Arcticzymes Technologies Asa · OSL:AZT
Arcticzymes Technologies Asa — SEB Healthcare Seminar 2024
11 slides from Arcticzymes Technologies Asa's conference presentation, Nov 20, 2024
Slide 1: SEB Healthcare Seminar
November 20, 2024 CEO Michael Akoh Enzymes that Unlock CFO Børge Sørvoll Your Next Discovery SEB Healthcare Seminar
Slide 2: Overview
Overview Overview AANorwegian Norwegianbiotech biotech with with growth growth potential potential A provider of novel Customers are life World class products and Targeting segments with Worldclass Products enzymes for advanced considerable growth therapies and molecular Segment & Customers science
Slide 3: B2B Value chain
B2B Value chain Biomanufacturing and Molecular Tools customers Biomanufacturing Customer Pharma / CDMO Hospitals over 300 Business-to-Business (B2B) customers Laboratories Researchers End-users 100,000s scientists, doctors, clinics Customer Diagnostics Molecular Tools
Slide 4: Best-in-class Enzymes
Best-in-class Enzymes Custom and OEM solutions – to meet customer’s needs Biomanufacturing Molecular Workflows (Therapeutics) (Research & Molecular Diagnostics) Viral vector, gene therapy and protein production Removal of nucleic acids during protein production, vaccine manufacturing and viral vecto
Slide 5: Strategic priorities
Strategic priorities Building a platform for long term growth – the journey has started Short Term Long Term Build Advanced therapies biomanufacturing pipeline to 1 Transformation to become customer centric 1 broaden and diversify portfolio Commercialization – strengthen commercial arm significantly
Slide 6: Partnerships Biomanufacturing and molecular tools
Partnerships Biomanufacturing and molecular tools
Slide 7: Increasing Commercial Reach
Increasing Commercial Reach OEM partnerships Expanding commercial channels: Selling direct as well as through partners Active Partner Engagement: Ongoing discussions with multiple potential partners Supply and Rebranding: ArcticZymes to provide bulk material for repackaging and rebranding under part
Slide 8: CDMO opportunities
CDMO opportunities Becoming the standard nuclease on a CDMO platform Trend in the CGT space - a return to the CDMO model Trough a partnership with CDMOs we will expand our reach significantly into several projects/clients M-SAN and SAN has been tested in an initial study with good data outcome at CD
Slide 9: The future portfolio - Diversification
The future portfolio - 9 Diversification
Slide 10: RNA based therapeutics
RNA based therapeutics Targeting a broader Advanced Therapies Market Enzymes are key in development, analytics and manufacturing process of mRNA AZT is now exploring new innovations in the field of RNA therapeutics through RCN funded collaboration project. First major innovation is a sequence specif
Slide 11: Thank you
ArcticZymes Technologies *
ArcticZymes Technologies — SEB Healthcare Seminar 2024 on 6ix